

CLONING AND EXPRESSION OF HUMAN URIDINE PHOSPHORYLASE*

Shin-Ichi Watanabe and Takafumi Uchida§

Departments of Oncology, Nippon Roche Research Center,
200 Kajiwara, Kamakura 247, Japan

Received September 21, 1995

Using a mouse cDNA probe we have identified a human uridine phosphorylase cDNA clone from the cDNA library of a human colorectal tumor cell line, HCT116. The recombinant human uridine phosphorylase expressed in COS-7 cells demonstrated specific enzyme activity with uridine as the substrate; this activity was inhibited by the competitive inhibitor 2,2'-anhydro-5-ethyluridine. Northern blot analysis with the cDNA as a probe demonstrated high levels of mRNA expression in several tumor cell lines but very low level in normal cell, WI-38. The expression of uridine phosphorylase mRNA in HCT-116 cells was further enhanced by treating the cells with vitamin D3 and the inflammatory cytokines: tumor necrosis factor α , interleukin 1 α and interferon γ . © 1995 Academic Press, Inc.

The two known kinds of pyrimidine nucleoside phosphorylases, uridine phosphorylase (UdRPase; EC 2.4.2.3) and thymidine phosphorylase (TdRPase; EC 2.4.2.4), in the presence of orthophosphate, catalyze the reversible phosphorolysis of uridine and thymidine or deoxyuridine, respectively, to free bases and ribose-1-phosphate or deoxyribose-1-phosphate. Pyrimidine nucleoside phosphorylases can add ribose or deoxyribose to pyrimidine bases to form nucleosides that can be

*Note: The nucleotide sequence data reported in this paper will appear in the GSDB, DDBJ, EMBL and NCBI nucleotide sequence databases with the following accession number X90858.

§Address Correspondence to: Dr. Takafumi Uchida, fax: +81-467-45-1675.

incorporated into RNA or DNA. Human TdRPase has been purified, cloned and shown to be identical to platelet-derived endothelial cell growth factor (PD-ECGF;1-3) and gliostatin (4), but human UdrPase has not been identified yet.

Recently we purified the murine UdrPase protein from a mouse cancer cell line, Colon-26, and cloned the cDNA (5). Using the mouse UdrPase probe, we cloned human UdrPase cDNA from a human colon cancer cell line, HCT116. We have tested the expression of the UdrPase gene in various human cancer cell lines and have found that upregulation occurs in HCT116 cells treated with cytokines and vitamin D3.

MATERIALS AND METHODS

Cell Lines-- The following 23 cell lines were cultured in optimal medium containing 10% fetal calf serum: normal fibroblast cell line (WI-38), gastric cancer cell lines (MKN1, MKN28, MKN45, AGS and KATO III), colon cancer cell lines (WiDr, HCT116, Lovo, DLD1, Colo201, Colo205, Colo320DM and CXF280), breast cancer cell lines (MCF-7, ZR-75-1 and MDA-MB-231), bladder cancer cell line (T-24), lung cancer cell line (A549), myeloblastic cell line (HL60), monocytoid cell line (U937), hepatoblastoma cell line (HepG2) and cervix cancer cell line (HeLa). HCT116 cells were separately treated with 1- α -25-dihydroxyvitamin D3 (final 200nM), human TNF α (final 1,000 units/ml), human IL-1 α (final 100 units/ml), human IFN γ (final 10units/ml) (all obtained from Hoffman-La-Roche, Basle, Switzerland). They were also treated with a combination of the above concentrations of the three kinds of cytokines. All cell lines were cultured for 24h in a humidified, 5% CO₂ atmosphere at 37°C.

Library Construction and Cloning-- Preparation of the mRNA from HCT116 cells, cDNA synthesis and ligation to λ gt11 were done as described previously (5,6). 5x10⁵ plaques were screened by the ³²P-labeled 1.3kb of mouse UdrPase cDNA probe. We obtained two independent clones having insert sizes of approximately 1.4 kb and 0.95 kb. These 1.4 kb and 0.95 kb cDNAs were subcloned into the mammalian expression vector pSG5 (7), pUP1-SG5 (1.4kb) and pUP2-SG5 (0.95kb).

cDNA Expression in COS-7 Cells and UdrPase assay-- 20 μ g each of pSG5, pUP1-SG5 and pUP2-SG5 were transfected into COS-7 cells by LipofectAMINE (GIBCO BRL). After the cells were incubated for 24 h, they were harvested and sonicated. The cell extracts were dialyzed against the reaction buffer and UdrPase was

assayed in the reaction mixture containing 50mM potassium phosphate buffer (pH 7.4) and 10 mM uridine or thymidine. UdrPase inhibitor, 2,2'-anhydro-5-ethyluridine (100 μ M) was added to the reaction mixture to test the substrate specificity. The enzyme reaction was performed at 37°C for 30 min and terminated by adding methanol. After removal of the precipitate by centrifugation, the supernatant was applied to a high-performance liquid chromatography column (6x200mm) of ERC-ODS-1171 (ERMA CR. Inc.). The amounts of uracil and thymine produced by phosphorolysis from uridine and thymidine were measured with a UV detector (265nm). The protein concentration was determined by the method of Lowry et. al. (8).

Northern Blotting and Hybridization-- Total RNA was extracted from log-phase cultures of the 23 cell lines, as well as from the vitamin D3 and cytokine- treated HCT116 cells. Then, 20 μ g of the total RNAs were separated by electrophoresis on 1% agarose gels and transferred onto nylon membranes (Hybond N; Amersham-Buchler, Braunsschweig, Germany). 32 P- labeled UdrPase cDNA and β -actin cDNA (control probe) were hybridized to the membranes.

RESULTS

Identification and Expression of UdrPase-- Two different sizes of cDNA were obtained from the HCT116 cDNA library; the longer one is 1349 bp, the shorter one, 965 bp. The complete sequence of the longer cDNA is shown in Fig.1; the underlined 392 nucleotides are spliced out from the longer cDNA to leave the shorter one. The sequences of human, murine and *E. coli* UdrPase proteins are compared in Fig. 2. The deduced amino acid sequence of the human UdrPase cDNA showed 78.5 % identity with that of the mouse UdrPase. The deduced amino acids of the shorter cDNA numbered only 36, because the frame was shifted.

The enzyme activity was examined by transfecting the cDNA into COS-7 cells and assaying the cell lysates with uridine. The longer cDNA- transfectant showed the uridine phosphorylase activity (Table 1) but the shorter cDNA- transfectant did not (data not shown). The substrate specificity of the UdrPase cDNA- transfectant was tested by two different substrates, uridine and thymidine. As summarized in Table 1, the specific activity of UdrPase in cells transfected with pUP1-SG5 was 54-fold higher than that in cells transfected with the vector alone when uridine was used as the substrate. There was little activity detected with thymidine. The enzymatic

```

ATTGAGTGTCCGGAGAACAGACCCGCGCCCGCGTCCGCGAGCCTCCCGAGAGCCGT 60
CCCTTCGTCCGGCCCTGGAGCATTGCGTTTGTGCGCCGGTGTGCGAGTGGAGGATGGCGC 120
CGCGGGTGTAGCGGCTCTCTGCGCAGGCCGAGTGGGCCAGAGAAGCGAGGAACCTCCCA 180
GATCGCCGACACGTCTCGTCTCTGTCCCAATTCAGGGCTTGGTGAGGTGACTCGCGGTC 240
GCGGGTGACTCGCGCGGAGACACTGCCTGGAACGCTGGAGCGCTCCCACTGCAGAGC 300

TCTGTCCGCCTCCAGCCGCTCTCTCTGACGGGTCTGCTCAGTTGGCGGAATGGCGGC 360
M A A

CACGGGAGCCAATGCAGAGAAAGCTGAAAGTCACAATGATTGCCCCGTGAGACTTTTAAA 420
T G A N A E K A E S H N D C P V R L L N

TCCAAACATAGCAAAAATGAAAGAAGATATTCTCTATCATTTCATCTCACCCTAGCAG 480
P N I A K M K E D I L Y H F N L T T S R

ACACAATTTCCAGCCTTGTGTTGGAGATGTGAAGTTTGTGTGTGTGGTGGGAAGCCCTC 540
H N F P A L F G D V K F V C V G G S P S

CCGGATGAAAGCCTTCATCAGGTGCGTTGGTGCAGAGCTGGGCCTTGACTGCCAGGTAG 600
R M K A F I R C V G A E L G L D C P G R

AGACTATCCCAACATCTGTGCGGGAAGTACCGCTATGCCATGTATAAGTAGGACCGGT 660
D Y P N I C A G T D R Y A M Y K V G P V

GCTGTCTGTGAGTCATGGTATGGGCATTCTTCTATCTCAATCATGTTGCATGAGCTCAT 720
L S V S H G M G I P S I S I M L H E L I

AAAGCTGCTGTACTATGCCGGTGTCTCAACGTCACATCATCCGATTGGCACTTCTGG 780
K L L Y Y A R C S N V T I I R I G T S G

TGGGATAGGTCTGGAGCCCGGCACTGTGGTCATAACAGAGCAGGCAGTGATACCTGCTT 840
G I G L E P G T V V I T E Q A V D T C F

CAAGGCAGAGTTTGAGCAGATTGTCTGGGGAAGCGGTATCCGAAAACGGACCTTAA 900
K A E F E Q I V L G K R V I R K T D L N

CAAGAAGCTGGTGCAGAGCTGTTGTGTGTTCTGCAGAGCTGAGCGAGTTCACCACAGT 960
K K L V Q E L L L C S A E L S E F T T V

GGTGGGGAACCATGTGCACCTTGGACTTCTATGAAGGGCAAGGCCGTCTGGATGGGGC 1020
V G N T M C T L D F Y E G Q G R L D G A

TCTCTGCTCTACACGGAGAAGACAAGCAGGCGTATCTGGAGGCAGCCTATGCAGCCGG 1080
L C S Y T E K D K Q A Y L E A A Y A A G

CGTCCGCAATATCGAGATGGAGTCTCGGTGTTTGGCCCATGTGCAGCGCCTGCGGCCT 1140
V R N I E M E S S V F A A M C S A C G L

CCAAGCGGCCGTGGTGTGTGTCACCTCCTGAACCGCCTGGAAGGGGACCAGATCAGCAG 1200
Q A A V V C V T L L N R L E G D Q I S S

CCCTCGCAATGTGCTCAGCGAGTACCAGCAGAGGCCGCGAGCGGTGGTGAGCTACTTCAT 1260
P R N V L S E Y Q Q R P Q R L V S Y F I

CAAGAAGAACTGAGCAAGGCTGAGCGCTGCCCTGCACCTCCGAGACCTGCTGTGATG 1320
K K K L S K A *

ACTTGCCATTAAAGCATTGTCCAAACCC 1349

```

Fig.1. Nucleotide and deduced amino acid sequence of human uridine phosphorylase. The deduced amino acid sequence is shown under the nucleotide sequence. The underline indicates the region of the nucleotide sequence deleted to form the shorter cDNA.

```

S-----KSDV---FHLGLTKNDLQG-
MAATGTEAKDLENHHNDCFIQLSNPNIAAMKEDVLYHFNLSTSTHDFPAM
MAATGANAEKAESHN-DCPVRLNPNIAKMKEDILYHFNLTTSRHNFPA
          * * . * . * . . . .

---ATLAIVPGDPDRVEKIAALMDKPVKLASH-REF-----TTWRAELD
FGDVKFVCVGGSSSRMNTFIKYVAELGLDHPGKEYPNICAGTDYAMYK
FGDVKFVCVGGSPSRMKAFIRCVGAELGLDCPGRDYPNICAGTDYAMYK
      . * * . * . . . * . . . * . *

GKPVIVCSTGIGGPSTSI AVEELAQL-----GIRTFRLRIGTTGAIQPHI
AGPVLVSVMGIPSGIMLHELKMLYHARCSNITIIIRIGTSGGIG--L
VGPVLVSVMGIPSGISIMLHELKLLYYARCSNVTIIIRIGTSGGIG--L
      ** . * * . * * . * . . . . . * . . . * . * .

NVGDVLVTASVR-----LDGASLHFAPLEFFPAVADF-ECTTAL
EPGSVVITQQAVNECFKPEFEQIVLGKRVIRNTNLDAQVLVQELVQCSSL
EPGTVVITEQAVDTCFKAEFEQIVLGKRVIRKTDLNKKLVQELLCSAEL
      . * * . * . * . . . . * . . . * . * . * . *

VEAAKSIGATTHVGVTTASSDTFYPGQERYD---TYSGRVVRHFKGSME
NEFFPMVVGNTM-----CTLDFYEGQGRLDGALCSYTEKDKQSY---LRA
SEFTTVVGNTM-----CTLDFYEGQGRLDGALCSYTEKDKQAY---LEA
      * . * * . * * * * * . * . . . .

WQAMGVVMNYEMESATLLTMCASQGLRAGMVAGVIVNRTQQEIPNA---ETM
AHAAGVRNIEMESSVFATMCGACGLKAAVVCVTLLDRLQGDQINTPHDVL
AYAAGVRNIEMESSVFAAMCSACGLQAAVVCVTLLNRLEGDQISSPRNV
      * * * * * . . . * . . * . . . * . . . . .

KQTESHAVKIVVEAARRLL---
VEYQQRQPRLVGHF IKKSLGRA
SEYQQRQPRLVS YFIKKLSKA
      . . . . . * . . . *

```

Fig.2. Alignment of the amino acid sequences of the *E.coli*, mouse and human uridine phosphorylase with clustal program. The asterisks and periods under the amino acid sequence indicate identical amino acids and conservative amino acid substitutions, respectively.

Table 1. Specific activities of recombinant human UdRPase in extracts of transfected COS-7 cells

Transfected gene	Substrate	
	Uridine*	Thymidine*
Human UdRPase-pSG5	300 ± 36	1.5 ± 0.34
pSG5 vector alone	5.6 ± 1.0	1.3 ± 0.62
% inhibition by 2,2'-anhydro-5-ethyluridine	88	N.D.

*10³ units/mg protein, where 1 unit = 1 μmol/min uracil or thymine converted from uridine or thymidine.
N.D. ; Not Done

activity of UdrPase was almost completely inhibited by 100 μ M 2,2'-anhydro-5-ethyluridine.

UdrPase Expression in Human Tumor Cell Lines and the Induction by Cytokines and Vitamin D3-- Northern blot analysis was used to examine the expression of UdrPase mRNA in 22 human tumor cell lines and one normal fibroblast cell line, WI-38. The RNA was detected in 13 of the 22 tumor lines, and little RNA was detected in WI-38. Expression of UdrPase was increased by treatment with vitamin D3 and the cytokines, TNF α , IL-1 α and IFN γ (Fig. 2).

DISCUSSION

Although there are two kinds of pyrimidine nucleoside phosphorylases in humans, TdrPase and UdrPase, only TdrPase has been identified as a platelet-derived endothelial cell growth factor, and human UdrPase has not been identified yet. To study the function of human UdrPase, we tried to identify human UdrPase. To begin with, we identified mouse UdrPase, because UdrPase levels are much higher in the mouse tumor cell lines than in human tumor cells. We have purified the enzyme from the murine colorectal cancer cell line Colon-26 and, based upon partial amino acid sequences, have cloned the full length gene (5). Then human UdrPase was identified from the human colorectal cancer cell line HCT116 by using the mouse UdrPase cDNA as a probe. The identity of the cloned gene was confirmed as being human UdrPase in several ways. First, the DNA sequence and the deduced amino acid sequence have high degrees of homology to those sequences for mouse UdrPase (Fig.2). Second, the recombinant protein, expressed in COS-7 cells, catalyzed the phosphorolysis of uridine specifically (Table 1). Finally, the activity of the enzyme was inhibited by a competitive inhibitor of UdrPase, 2,2'-anhydro-5-ethyluridine, (Table 1).

We have demonstrated that UdrPase mRNA is expressed in various kinds of tumor cell lines (Fig.3a), although the activity of UdrPase in various human tumor samples is very low as compared with that of TdrPase (data not shown). UdrPase expression is increased in HCT116 cells as well as in the murine colorectal tumor cell line Colon-26, in response to a mixture of the cytokines TNF α , IL-1 α and IFN γ . The expression of the TdrPase gene is also up-regulated in human cancer cells by these cytokines (9).

In conclusion, we have cloned human UdrPase cDNA and shown that its expression is regulated at the mRNA level by cytokines and vitamin D3. Further




Fig.3. Northern blot analysis of human uridine phosphorylase expression. 20 mg of total RNA from 1: WI38, 2: WiDr, 3: HCT116, 4: DLD-1, 5: Lovo, 6: CXF280, 7: Colo201, 8: Colo205, 9: Colo320DM, 10: AGS, 11: KATO III, 12: MKN1, 13: MKN28, 14: MKN45, 15: ZR-75-1, 16: MCF-7, 17: MDA-MB-231, 18: HL60, 19: U937, 20: A549, 21: HepG2, 22: T-24 and 23: HeLa were used as samples.

b: 20 μ g of total RNA from HCT116 cells treated with nothing (1), vitamin D3 (2), TNF α (3), IL-1 α (4), IFN γ (5) and the mixture of TNF α , IL-1 α and IFN γ (6) were used as samples.

studies of this gene should help us to determine the relative roles of UdRPase and TdRPase in human tumor cells.

REFERENCES

1. Usuki, K., Saras, J., Waltenberger, J., Miyazono, K., Pierce, G., Thomason, A. and Heldin, C.-H. (1992) *Biochem. Biophys. Res. Commun.* **184**, 1311-1316
2. Furukawa, T., Yoshimura, A., Sumizawa, T., Haraguchi, M. and Akiyama, S.I. (1992) *Nature* **356**, 668
3. Moghaddam, A. and Bicknell, R. (1992) *Biochemistry* **31**, 12141-12146
4. Asai, K., Nakanishi, K., Isobe, I., Eksioglu, Y.Z., Hirano, A., Hama, K., Miyamoto, T. and Kato, T. (1992) *J. Biol. Chem.* **267**, 20311-20316

5. Watanabe, S.-I., Hino, A., Wada, K., Eliason, J.F. and Uchida, T. (1995) *J Biol Chem* **270**, 12191-12196
6. Sambrook, J., Fritsch, E.F. and Maniatis, T. (1989) *Molecular Cloning: A Laboratory Manual*, 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
7. Green, S., Issemann, I. and Sheer, E. (1988) *Nucleic Acids Res.* **16**, 369
8. Lowry, O.H., Rosebrough, N.J., Farr, A.L. and Randall, R.J. (1951) *J. Biol. Chem.* **193**, 265-275
9. Eda, H., Fujimoto, K., Watanabe, S.I., Ura, M., Hino, A., Tanaka, Y., Wada, K. and Ishitsuka, H. (1993) *Cancer Chemotherapy and Pharmacology* **32**, 333-338